0001140361-14-046592.txt : 20141229
0001140361-14-046592.hdr.sgml : 20141225
20141229174029
ACCESSION NUMBER: 0001140361-14-046592
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141223
FILED AS OF DATE: 20141229
DATE AS OF CHANGE: 20141229
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 141313637
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
doc1.xml
FORM 4
X0306
4
2014-12-23
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54, RUE LA BOETIE
PARIS
I0
75008
FRANCE
0
0
1
0
Common Stock
2014-12-23
4
P
0
1190
384.4259
A
22658875
I
See note
Common Stock
2014-12-23
4
P
0
16813
385.5228
A
22675688
I
See note
Common Stock
2014-12-23
4
P
0
17013
386.4523
A
22692701
I
See note
Common Stock
2014-12-23
4
P
0
5500
388.0395
A
22698201
I
See note
Common Stock
2014-12-23
4
P
0
15104
389.1733
A
22713305
I
See note
Common Stock
2014-12-23
4
P
0
12046
389.8806
A
22725351
I
See note
Common Stock
2014-12-23
4
P
0
2550
391.2539
A
22727901
I
See note
Common Stock
2014-12-23
4
P
0
8030
392.9571
A
22735931
I
See note
Common Stock
2014-12-23
4
P
0
16393
393.9927
A
22752324
I
See note
Common Stock
2014-12-23
4
P
0
47730
394.8543
A
22800054
I
See note
Common Stock
2014-12-23
4
P
0
2868
396.6363
A
22802922
I
See note
Common Stock
2014-12-23
4
P
0
16237
397.7191
A
22819159
I
See note
Common Stock
2014-12-23
4
P
0
9983
398.1565
A
22829142
I
See note
Common Stock
2014-12-24
4
P
0
1100
392.7173
A
22830242
I
See note
Common Stock
2014-12-24
4
P
0
700
393.8886
A
22830942
I
See note
Common Stock
2014-12-24
4
P
0
890
395.5299
A
22831832
I
See note
Common Stock
2014-12-24
4
P
0
1700
396.6641
A
22833532
I
See note
Common Stock
2014-12-24
4
P
0
2067
397.5334
A
22835599
I
See note
Common Stock
2014-12-24
4
P
0
3300
398.7791
A
22838899
I
See note
Common Stock
2014-12-24
4
P
0
20245
399.7415
A
22859144
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $384.00 to $384.81 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,059,592 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Purchase prices range from $385.00 to $385.92 per share, inclusive.
Purchase prices range from $386.00 to $386.96 per share, inclusive.
Purchase prices range from $387.52 to $388.50 per share, inclusive.
Purchase prices range from $388.60 to $389.59 per share, inclusive.
Purchase prices range from $389.60 to $390.49 per share, inclusive.
Purchase prices range from $391.04 to $391.61 per share, inclusive.
Purchase prices range from $392.39 to $393.37 per share, inclusive.
Purchase prices range from $393.48 to $394.44 per share, inclusive.
Purchase prices range from $394.48 to $395.00 per share, inclusive.
Purchase prices range from $395.98 to $396.97 per share, inclusive.
Purchase prices range from $396.99 to $397.98 per share, inclusive.
Purchase prices range from $397.99 to $398.56 per share, inclusive.
Purchase prices range from $392.57 to $393.11 per share, inclusive.
Purchase prices range from $393.79 to $393.92 per share, inclusive.
Purchase prices range from $395.14 to $395.76 per share, inclusive.
Purchase prices range from $396.19 to $397.16 per share, inclusive.
Purchase prices range from $397.23 to $398.10 per share, inclusive.
Purchase prices range from $398.26 to $399.23 per share, inclusive.
Purchase prices range from $399.27 to $400.00 per share, inclusive.
/s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law
2014-12-29